TY - JOUR AU - Jain, K. K. PY - 2000 DA - 2000// TI - Evaluation of intravenous parecoxib for the relief of acute post-surgical pain JO - Expert Opin Investig Drugs VL - 9 UR - https://doi.org/10.1517/13543784.9.11.2717 DO - 10.1517/13543784.9.11.2717 ID - Jain2000 ER - TY - JOUR AU - Daniels, S. E. AU - Grossman, E. H. AU - Kuss, M. E. AU - Talwalker, S. AU - Hubbard, R. C. PY - 2001 DA - 2001// TI - A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model JO - Clin Ther VL - 23 UR - https://doi.org/10.1016/S0149-2918(01)80088-6 DO - 10.1016/S0149-2918(01)80088-6 ID - Daniels2001 ER - TY - JOUR AU - Gajraj, N. M. PY - 2003 DA - 2003// TI - Cyclooxygenase-2 inhibitors JO - Anesth Analg VL - 96 UR - https://doi.org/10.1213/01.ANE.0000061461.55712.C5 DO - 10.1213/01.ANE.0000061461.55712.C5 ID - Gajraj2003 ER - TY - JOUR AU - Noveck, R. J. AU - Hubbard, R. C. PY - 2004 DA - 2004// TI - Parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters JO - J Clin Pharmacol VL - 44 UR - https://doi.org/10.1177/0091270004264166 DO - 10.1177/0091270004264166 ID - Noveck2004 ER - TY - JOUR AU - Aldington, S. AU - Shirtcliffe, P. AU - Weatherall, M. AU - Beasley, R. PY - 2005 DA - 2005// TI - Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis JO - N Z Med J VL - 118 ID - Aldington2005 ER - TY - STD TI - Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003;125(6):1481–92. ID - ref6 ER - TY - STD TI - Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New Engl J Med. 2005;352(11):1081–91. ID - ref7 ER - TY - STD TI - Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med. 2005;352(11):1071–80. ID - ref8 ER - TY - STD TI - Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, et al. 4-[5-methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem. 2000;43(5):775–7. ID - ref9 ER - TY - JOUR AU - Karim, A. AU - Laurent, A. AU - Slater, M. E. AU - Kuss, M. E. AU - Qian, J. AU - Crosby-Sessoms, S. L. PY - 2001 DA - 2001// TI - A pharmacokinetic study of intramuscular (IM) parecoxib sodium in normal subjects JO - J Clin Pharmacol VL - 41 UR - https://doi.org/10.1177/00912700122012607 DO - 10.1177/00912700122012607 ID - Karim2001 ER - TY - JOUR AU - Ibrahim, A. E. AU - Feldman, J. AU - Karim, A. AU - Kharasch, E. D. PY - 2003 DA - 2003// TI - Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil JO - Anesthesiology. VL - 98 UR - https://doi.org/10.1097/00000542-200304000-00011 DO - 10.1097/00000542-200304000-00011 ID - Ibrahim2003 ER - TY - JOUR AU - Zhou, S. F. AU - Zhou, Z. W. AU - Yang, L. P. AU - Cai, J. P. PY - 2009 DA - 2009// TI - Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development JO - Curr Med Chem VL - 16 UR - https://doi.org/10.2174/092986709789057635 DO - 10.2174/092986709789057635 ID - Zhou2009 ER - TY - JOUR AU - Preissner, S. AU - Kroll, K. AU - Dunkel, M. AU - Senger, C. AU - Goldsobel, G. AU - Kuzman, D. PY - 2010 DA - 2010// TI - SuperCYP: a comprehensive database on cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions JO - Nucleic Acids Res VL - 38 UR - https://doi.org/10.1093/nar/gkp970 DO - 10.1093/nar/gkp970 ID - Preissner2010 ER - TY - JOUR AU - Vera, L. AU - Long, J. R. PY - 2015 DA - 2015// TI - Dynastat frequency divider with DC-153 GHz range JO - Electron Lett VL - 51 UR - https://doi.org/10.1049/el.2015.0050 DO - 10.1049/el.2015.0050 ID - Vera2015 ER - TY - JOUR AU - Talley, J. J. AU - Bertenshaw, S. R. AU - Brown, D. L. AU - Carter, J. S. AU - Graneto, M. J. AU - Kellogg, M. S. PY - 2000 DA - 2000// TI - N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl] sulfonyl] propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration JO - J Med Chem VL - 43 UR - https://doi.org/10.1021/jm000069h DO - 10.1021/jm000069h ID - Talley2000 ER - TY - JOUR AU - Sarapa, N. AU - Britto, M. R. AU - Mainka, M. B. AU - Parivar, K. PY - 2005 DA - 2005// TI - The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor JO - Eur J Clin Pharmacol VL - 61 UR - https://doi.org/10.1007/s00228-005-0909-6 DO - 10.1007/s00228-005-0909-6 ID - Sarapa2005 ER - TY - JOUR AU - Agundez, J. A. G. AU - Garcia-Martin, E. AU - Martinez, C. PY - 2009 DA - 2009// TI - Genetically based impairment in CYP2C8-and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? JO - Expert Opin Drug Metab Toxicol VL - 5 UR - https://doi.org/10.1517/17425250902970998 DO - 10.1517/17425250902970998 ID - Agundez2009 ER - TY - JOUR AU - Karim, A. AU - Laurent, A. AU - Slater, M. E. AU - Kuss, M. E. AU - Qian, J. AU - Crosby-Sessoms, S. L. PY - 2001 DA - 2001// TI - A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects JO - J Clin Pharmacol VL - 41 UR - https://doi.org/10.1177/00912700122012607 DO - 10.1177/00912700122012607 ID - Karim2001 ER - TY - JOUR AU - Jin, X. AU - Zhou, F. AU - Liu, Y. AU - Cheng, C. AU - Yao, L. AU - Jia, Y. PY - 2018 DA - 2018// TI - Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice JO - J Pharm Biomed Anal VL - 158 UR - https://doi.org/10.1016/j.jpba.2018.05.034 DO - 10.1016/j.jpba.2018.05.034 ID - Jin2018 ER - TY - JOUR AU - Liu, M. AU - Yu, Q. AU - Li, P. AU - Zhu, M. AU - Fang, M. AU - Sun, B. PY - 2016 DA - 2016// TI - Simultaneous determination of parecoxib sodium and its active metabolite valdecoxib in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study after intravenous and intramuscular administration JO - J Chromatogr B Analyt Technol Biomed Life Sci. VL - 1022 UR - https://doi.org/10.1016/j.jchromb.2016.04.009 DO - 10.1016/j.jchromb.2016.04.009 ID - Liu2016 ER - TY - JOUR AU - Zhang, L. AU - Wang, A. AU - Wang, X. AU - Zhang, Y. AU - Li, X. AU - Liu, P. PY - 2014 DA - 2014// TI - Simultaneous determination of Guanfu base G and its active metabolites by UPLC-MS/MS in rat plasma and its application to a pharmacokinetic study JO - J Chromatogr B Analyt Technol Biomed Life Sci. VL - 957 UR - https://doi.org/10.1016/j.jchromb.2014.02.024 DO - 10.1016/j.jchromb.2014.02.024 ID - Zhang2014 ER - TY - JOUR AU - Saccomanni, G. AU - Giorgi, M. AU - Carlo, S. AU - Manera, C. AU - Saba, A. AU - Macchia, M. PY - 2011 DA - 2011// TI - Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology JO - Anal Bioanal Chem VL - 401 UR - https://doi.org/10.1007/s00216-011-5244-4 DO - 10.1007/s00216-011-5244-4 ID - Saccomanni2011 ER - TY - JOUR AU - Wu, Z. AU - Gao, W. AU - Phelps, M. A. AU - Wu, D. AU - Miller, D. D. AU - Dalton, J. T. PY - 2004 DA - 2004// TI - Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry JO - Anal Chem VL - 76 UR - https://doi.org/10.1021/ac0351670 DO - 10.1021/ac0351670 ID - Wu2004 ER -